Pacific Bio (PACB) Tops Q4 EPS by 1c

Pacific Bio (NASDAQ: PACB) reported Q4 EPS of ($0.27), $0.01 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $58.36 million versus the consensus estimate of $56.96 million.

For earnings history and earnings-related data on Pacific Bio (PACB) click here.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• Piper Sandler: 'DENTSPLY SIRONA (XRAY) most at risk; Own Manufacturers at Your Own Risk'
• Rosenblatt Reiterates Buy Rating on Walt Disney (DIS)